There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session with the FDA's Advisory...

There is unlikely to be any pain relief for QRX investors tomorrow as the company heads into what looks to be a challenging session with the FDA's Advisory Committee meeting overnight. The briefing documents were posted on the FDA website over the weekend and the Agency make it pretty clear they are non-plussed with QRX's third attempt to get its blessing. QRX's pain drug is somewhat unusual in that it combines two drugs of the same class which has made it more difficult for the Agency to evaluate. However, after running their own analysis, the FDA decided that they could not see any evidence that it worked better. QRX believed their data showed that the combo product had lower rates of respiratory depression but the Agency does not appear to be convinced about this or any other safety benefits. Whatever happens, overnight, it is not going to be pretty.